Merck
すべての画像(1)

資料

PZ0320

Sigma-Aldrich

PF-04937319

≥98% (HPLC)

すべての画像(1)
別名:
N, N-Dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide, N,N-Dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]-2-pyrimidinecarboxamide
Empirical Formula (Hill Notation):
C22H20N6O4
CAS番号:
1245603-92-2
分子量:
432.43
MDL番号:
MFCD26960571
PubChem Substance ID:
329823838
NACRES:
NA.77

品質水準

100

アッセイ

≥98% (HPLC)

形状

powder

manufacturer/tradename

Pfizer®

色

white to beige

溶解性

DMSO: 20 mg/mL, clear

オーガナイザー

Pfizer

保管温度

room temp

SMILES string

CC(O1)=CC2=C1C=C(C(NC3=NC=C(C)N=C3)=O)C=C2OC4=CN=C(C(N(C)C)=O)N=C4

InChI

1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)

InChI key

MASKQITXHVYVFL-UHFFFAOYSA-N

関連するカテゴリー

類似品目との比較

比較内容をすべて表示

Show Differences

1 of 4

当該品目
PZ0318PZ0319PZ0263
PF-04937319 ≥98% (HPLC)

Sigma-Aldrich

PZ0320

PF-04937319

PF-06761281 ≥97% (HPLC)

Sigma-Aldrich

PZ0318

PF-06761281

PF-06409577 ≥98% (HPLC)

Sigma-Aldrich

PZ0319

PF-06409577

PF-3774076 ≥98% (HPLC)

Sigma-Aldrich

PZ0263

PF-3774076

form

powder

form

powder

form

powder

form

powder

manufacturer/tradename

Pfizer®

manufacturer/tradename

Pfizer®

manufacturer/tradename

Pfizer®

manufacturer/tradename

Pfizer®

color

white to beige

color

white to beige

color

white to beige

color

white to beige

solubility

DMSO: 20 mg/mL, clear

solubility

H2O: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 10 mg/mL, clear

originator

Pfizer

originator

Pfizer

originator

Pfizer

originator

Pfizer

詳細

PF-04937319 is a partial activator of glycokinase (GK) enzyme.

生物化学的／生理学的作用

PF-04937319 is a glucokinase activator with an EC50 value of 174 nM. PF-04937319 was found to improve glycemic control in adults with type 2 diabetes when used in conjunction with metformin.
PF-04937319, unlike other glucokinase activators, is capable of maintaining lower-glucose levels without it resulting in hypoglycemia. In type II diabetic patients where metformin treatment is inadequate, PF-04937319 is capable of maintaining glycemic control within the acceptable risk-benefit profile.

その他情報

This compound was developed by Pfizer for Cytokines & Growth Factors research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

法的情報

Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

ウェブサイトの表示では、製品番号に容量／数量が連結しています（例：T1503-25G）。確認してください 製品番号欄には製品番号のみを入力してください (例 T1503).

例

T1503
製品番号
-
25G
容量／数量

その他の例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

入力例：1.000309185)

ご不明な点がございましたら、お気軽にお問い合わせくださいテクニカルサービス お問い合わせ

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich製品

  • もしTO09019TOなどのロット番号を見つけた場合は、最初の2文字を除いたロット番号09019TOを入力します。

  • もし05427ES-021などの充てんコード付きロット番号を見つけた場合は、充てんコードの-021を除いたロット番号05427ESを入力します。

  • もしSTBB0728K9などの充てんコード付きロット番号を見つけた場合は、充てんコードのK9を除いたロット番号STBB0728を入力します。

お探しのものが見つかりませんか？

オンラインでCOAを入手できない場合があります。検索してもCOAが見つからない場合は、リクエストできます。

COAをリクエストする

Raman Sharma et al.
Drug metabolism and disposition: the biological fate of chemicals, 42(11), 1926-1939 (2014-08-22)
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide (PF-04937319), which is under development for the treatment of type 2 diametes mellitus. Metabolic profiling in rat, dog, and human hepatocytes revealed that PF-04937319 is
John C Pettersen et al.
Toxicologic pathology, 42(4), 696-708 (2014-04-29)
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF-04651887, piragliatin, and PF-04937319) was assessed in mice, rats, dogs, and/or monkeys. GKAs were administered for 2 to 8 weeks. Standard
N B Amin et al.
Diabetes, obesity & metabolism, 17(8), 751-759 (2015-04-18)
To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to once-daily PF-04937319 doses of 10

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

テクニカルサービス連絡先